Ayman Haj Asaad
Advanced Heart Failure and Transplant Cardiology · Birmingham, ALNPI 1144348632
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $3,938 of the $5,159 with a category attached, or 76.3%. Medtronic accounts for 63.9% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2019 at $4,926 and has fallen 95.3% since, to $231 in 2025.
Across 29 payments — averaging $177.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Abbott$2K
- Abiomed$125
- United Therapeutics Corporation$35
- E.r. Squibb & Sons, L.L.C.$20
Across 1 payment — averaging $40,700 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$41K
What the payments were for
- Travel & lodging$3,93876%
- Food & beverage$1,21924%
- Education$30%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 13 | $3,296 |
| Abbott | 12 | $1,683 |
| Abiomed | 1 | $125 |
| United Therapeutics Corporation | 2 | $35 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- HeartWare HVAD$2,992
- HeartMate PHP$1,336
How this compares
Too few advanced heart failure and transplant cardiology providers in Alabamato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tyvaso DpiTreprostinil | 31 | $759,419 |
| Ambrisentan | 140 | $407,204 |
| AdempasRiociguat | 23 | $324,311 |
| LetairisAmbrisentan | 23 | $295,736 |
| JardianceEmpagliflozin | 235 | $270,177 |
| EntrestoSacubitril/Valsartan | 187 | $223,385 |
| OpsumitMacitentan | 16 | $191,390 |
| Orenitram ErTreprostinil Diolamine | 26 | $104,863 |
| EliquisApixaban | 59 | $58,074 |
| Tadalafil | 53 | $44,591 |
| Isosorbide Dinitrate | 28 | $15,257 |
| FarxigaDapagliflozin Propanediol | 14 | $13,333 |
| Sildenafil Citrate | 77 | $11,894 |
| XareltoRivaroxaban | 12 | $10,750 |
| Potassium Chloride | 65 | $2,107 |
Paid to pharmacies, not to this prescriber.
Other advanced heart failure and transplant cardiology in Birmingham
- Indranee RajapreyarBirmingham$6K
- Heriberto Matos SantanaBirmingham$3K
- Jose TallajBirmingham$821
- Kenneth BurnhamMobile$446K
- Kaushik JainHuntsville$80K
- David SmullDecatur$20K
- Luanda GrazetteMobile$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.